Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAREG: Bevacizumab vs Fotemustine in Recurrent Glioblastoma
NCT01474239Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2011
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in glioblastoma multiforme (GBM) (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants Alive 6 Months After Start of Treatment and Overall Survival up to 691 days. Started Nov 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01474239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01474239.